Summary:
This is a new study for patients with recently diagnosed Type 1 Diabetes. It seeks to demonstrate that patients who receive an 8-day series of Otelixizumab infusions have greater improvement than subjects who receive placebo.
Qualified Participants Must:
• Be 18 and 35 years of age
•
Have been recently diagnosed (within the past 90 days) with Type 1 Diabetes requiring insulin treatment
Qualified Participants May Receive:
Medical supervision and care, labs, and study medication free of charge. Compensation is available up to $1,500. Also, transportation is available upon request.